Organization
Blueprint Medicines
15 clinical trials
4 abstracts
71 posters
Clinical trial
Phase I/II Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion MutationsStatus: Active (not recruiting), Estimated PCD: 2024-08-23
Clinical trial
A Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of BLU-554 in Patients With Hepatocellular CarcinomaStatus: Completed, Estimated PCD: 2021-06-30
Clinical trial
A Phase 1/2 Study Targeting Acquired Resistance Mechanisms in Patients With EGFR Mutant Non-Small Cell Lung CancerStatus: Active (not recruiting), Estimated PCD: 2025-01-31
Clinical trial
A Phase 1/2, Open-label, 2-arm Study Evaluating BLU-263 as Monotherapy and in Combination With Azacitidine, in Patients With KIT Altered Hematologic MalignanciesStatus: Recruiting, Estimated PCD: 2029-11-30
Clinical trial
A Phase 1/2 Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of BLU-222 as a Single Agent and in Combination Therapy for Patients With Advanced Solid TumorsStatus: Recruiting, Estimated PCD: 2025-11-30
Clinical trial
A Drug-drug Interaction Study to Investigate the Effect of Avapritinib on the Pharmacokinetics of Midazolam in Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors (GIST) and Other Advanced Solid TumorsStatus: Completed, Estimated PCD: 2024-03-01
Clinical trial
A Phase 1 Study of BLU-285 in Patients With Advanced Systemic Mastocytosis (AdvSM) and Relapsed or Refractory Myeloid MalignanciesStatus: Completed, Estimated PCD: 2022-10-05
Clinical trial
A Phase 1/2, Single-arm Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of Avapritinib in Pediatric Patients With Solid Tumors Dependent on KIT or PDGFRA SignalingStatus: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
A 3-Part, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate Safety and Efficacy of Avapritinib (BLU-285), a Selective KIT Mutation-Targeted Tyrosine Kinase Inhibitor, in Indolent and Smoldering Systemic Mastocytosis With Symptoms Inadequately Controlled With Standard TherapyStatus: Active (not recruiting), Estimated PCD: 2027-06-23
Clinical trial
An International, Multicenter, Open-label, Randomized, Phase 3 Study of BLU-285 vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic Gastrointestinal Stromal Tumor (GIST)Status: Completed, Estimated PCD: 2020-03-09
Clinical trial
A Phase 1/2 Study of the Highly Selective EGFR Inhibitor, BLU-701, in Patients With EGFR-Mutant Non-Small Cell Lung CancerStatus: Terminated, Estimated PCD: 2022-12-09
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study of BLU-263 in Indolent Systemic MastocytosisStatus: Recruiting, Estimated PCD: 2028-06-30
Clinical trial
Extension Protocol for Patients Previously Treated in Avapritinib Clinical TrialsStatus: Active (not recruiting), Estimated PCD: 2025-08-01
Clinical trial
An Open-label, Single Arm, Phase 2 Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic MastocytosisStatus: Active (not recruiting), Estimated PCD: 2026-01-31
Poster
Safety and pharmacokinetics of BLU-263, a next-generation KIT inhibitor, in healthy volunteersPoster
BLU-701 Lung CancerPoster
BLU-808, a Potent and Selective Small Molecule Inhibitor of Wild-Type KIT for Mast Cell DisordersPoster
BLU-808, a Potent and Selective Small Molecule Inhibitor of Wild-Type KIT for Mast Cell DisordersPoster
Updated ARROW data: pralsetinib in patients with advanced or metastatic RET-altered thyroid cancerAbstract
BLU-222, an investigational, oral, potent, and highly selective CDK2 inhibitor (CDK2i), as monotherapy in patients (pts) with advanced solid tumors and in combination with ribociclib (RIBO) and fulvestrant (FUL) in HR+/HER2− breast cancer (BC).Org: Henri and Belinda Termeer Center for Targeted Therapies, Massachusetts General Hospital, Boston, MA, USA, Massachusetts General Hospital, Florida Cancer Specialists/Sarah Cannon Research Institute, University of Virginia, Charlottesville, VA, USA, Memorial Sloan Kettering Cancer Center,
Abstract
BLU-222, an oral, potent, and selective CDK2 inhibitor, in patients with advanced solid tumors: Phase 1 monotherapy dose escalation.Org: Florida Cancer Specialists and Sarah Cannon Research Institute, Sarasota, FL, USA, Henri and Belinda Termeer Center for Targeted Therapies, Massachusetts General Hospital, Boston, MA, USA, Massachusetts General Hospital, Columbia University Irving Medical Center, New York, NY, USA, University of Virginia, Charlottesville, VA, USA,
Abstract
Emerging phase 1 data of BLU-451 in advanced NSCLC with EGFR exon 20 insertions.Org: City of Hope- Long Beach Elm, Perlmutter Cancer Center, New York University Langone Health, Fred Hutchinson Cancer Center/Division of Hematology and Oncology, Dana-Farber Cancer Institute, Northwestern Medicine Devleopmental Therapeutics Institute,
Abstract
BLU-945 monotherapy and in combination with osimertinib (OSI) in previously treated patients with advanced EGFR-mutant (EGFRm) NSCLC in the phase 1/2 SYMPHONY study.Org: Blueprint Medicines, Sarah Cannon Research Institute/Tennessee Oncology, Perlmutter Cancer Center, New York University Langone Health, Gustave Roussy, Department of Medical Oncology, Thoracic Group,